What question did this study set out to answer?

To evaluate neutralizing antibody and variant-specific T cell responses against SARS-CoV-2 variants of concern, specifically Omicron, across multiple COVID-19 vaccine regimens.

February 3, 2022Science ImmunologyOpen Access

Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients

View Full Paper

Ask AI

Bookmark

Authors

CGCorine H. GeurtsvanKessel DGDaryl Geers KSKatharina S. Schmitz

Discussion

Member takes

Overview

Cohort study demonstrates preserved T cell responses despite sharply reduced Omicron neutralization in vaccinated workers, suggesting cellular immunity still limits severe disease.

Key Points

To evaluate neutralizing antibody and variant-specific T cell responses against SARS-CoV-2 variants of concern, specifically Omicron, across multiple COVID-19 vaccine regimens.
Prospective cohort study of 60 healthcare workers vaccinated with ChAdOx-1 S, Ad26.COV2.S, mRNA-1273, or BNT162b2, with follow-up through 6 months post-immunization.
Assessed binding antibodies, neutralization titers against wild-type (D614G), Beta, Delta, and Omicron variants, and variant-specific CD4+ and CD8+ T cell responses, including after BNT162b2 booster vaccination.
Neutralization against the Omicron variant was significantly reduced or undetectable across all primary regimens; BNT162b2 booster doses partially restored neutralization, though titers remained up to 17-fold lower than against wild-type.
Spike-specific CD4+ and CD8+ T cells persisted up to 6 months across all vaccine platforms, demonstrating no significant loss of reactivity against variants of concern, including Omicron.

Cite This Study

GeurtsvanKessel et al. (2022) studied this question.

synapsesocial.com/papers/69da6b41ae64bec32b835d37 https://doi.org/10.1126/sciimmunol.abo2202

View Full Paper

Ask AI

Bookmark

February 3, 2022Science ImmunologyOpen Access

Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients

View Full Paper

Ask AI

Bookmark

Authors

CGCorine H. GeurtsvanKessel DGDaryl Geers KSKatharina S. Schmitz

Discussion

Member takes

Overview

Cohort study demonstrates preserved T cell responses despite sharply reduced Omicron neutralization in vaccinated workers, suggesting cellular immunity still limits severe disease.

Key Points

To evaluate neutralizing antibody and variant-specific T cell responses against SARS-CoV-2 variants of concern, specifically Omicron, across multiple COVID-19 vaccine regimens.
Prospective cohort study of 60 healthcare workers vaccinated with ChAdOx-1 S, Ad26.COV2.S, mRNA-1273, or BNT162b2, with follow-up through 6 months post-immunization.
Assessed binding antibodies, neutralization titers against wild-type (D614G), Beta, Delta, and Omicron variants, and variant-specific CD4+ and CD8+ T cell responses, including after BNT162b2 booster vaccination.
Neutralization against the Omicron variant was significantly reduced or undetectable across all primary regimens; BNT162b2 booster doses partially restored neutralization, though titers remained up to 17-fold lower than against wild-type.
Spike-specific CD4+ and CD8+ T cells persisted up to 6 months across all vaccine platforms, demonstrating no significant loss of reactivity against variants of concern, including Omicron.

Cite This Study

GeurtsvanKessel et al. (2022) studied this question.

synapsesocial.com/papers/69da6b41ae64bec32b835d37 https://doi.org/10.1126/sciimmunol.abo2202

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark